The global Sepsis Diagnostics Market size is expected to reach USD 1.4 billion by 2030, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 9.6% over the forecast period. The high prevalence of sepsis, the introduction of technologically advanced diagnostic systems, and increasing government initiatives are expected to propel market growth over the forecast period. Sepsis is a bloodstream disease that occurs as a result of a response to pathogenic microorganisms present in the blood. Patients suffering from this disease experience severe inflammation, which leads to prolonged hospitalization.
According to the WHO, around 30 million people are estimated to be affected by this disease every year. The NCBI stated that the largest number of this condition have been observed in the youngest and oldest age groups. Thus, there is a rising need for the early diagnosis of this disease. The WHO reported that every year, 1.2 million children and 3 million newborns are affected by this disease across the world. This has further boosted the demand for its diagnostic tools for quick results and improved patient outcomes. Increasing regulatory approval and the introduction of technologically advanced diagnostic solutions for sepsis are expected to facilitate market growth over the forecast period.
In May 2018, T2 Biosystems, Inc., a U.S.-based emerging diagnostic solutions company, received the U.S. FDA approval for its T2Bacteria Panel, intended for the detection of specific sepsis-causing bacterial pathogens in human whole blood specimens. The COVID-19 pandemic affected the growth of diagnostics products for sepsis in a moderately positive way. The worldwide spread of Coronavirus and the arising instances of sepsis among COVID-19 patients are probably going to expand the interest for fast detection, speeding up the use of instruments, reagents, and assay kits for recognition of sepsis. Pandemic-induced lockdown and other restrictions made individuals delay going through wellbeing checkups, influencing the number of tests performed and reagent deals.
The pandemic has featured the risk upon elders, who are more defenseless to complications, including intense respiratory distress condition, typically because of pneumonia, which builds the risk of creating sepsis. This has created a need for the early detection of sepsis among patients with COVID-19. Symptoms of sepsis, such as multiorgan injuries, develop in around 2.0 to 5.0% of COVID-19 cases 8 to 10 days post-hospitalization, based on the estimates of the Global Sepsis Alliance. To manage this situation, the Biomedical Advanced Research and Development Authority, in May 2020, extended its partnership with Beckman Coulter for the development of a digital algorithm to detect sepsis in patients with COVID-19.
Related Press Release@ Sepsis Diagnostics Market Report
Sepsis Diagnostics Market Report Highlights
- By product, blood culture media held the largest share in 2021 as it is the most accurate mode of testing for the diagnosis of this disease. It is also anticipated to witness the fastest CAGR over the forecast period owing to new product developments in this field
- The microbiology technology segment had the largest share in 2021 and the molecular diagnostics segment is anticipated to exhibit a lucrative CAGR over the forecast period owing to its high sensitivity, accuracy, and less turnaround time
- The bacterial pathogen segment held the largest revenue share in 2021 owing to the high prevalence of bacterial sepsis
- The laboratory testing type segment dominated the market in 2021 and accounted for the maximum revenue share on account of the better accuracy of these tests
- North America dominated the market in 2021 due to a favorable reimbursement scenario, the presence of established players, and high awareness about sepsis & its diagnosis
- Middle East Africa is projected to witness a lucrative growth rate over the forecast period owing to the presence of a large target population in emerging economies, such as Algeria and Morocco
